STAT+: Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic

With an eye toward pandemic preparedness, a U.N.-backed agency has signed sub-licensing deals with 11 manufacturers to develop and manufacture generic versions of a Roche influenza treatment. Under the agreements, brokered by the Medicines Patent Pool, the companies can develop, manufacture, and supply Xofluza in 129 countries, covering nearly all low- and middle-income nations. The manufacturers will also have access to technical data, reference products for bioequivalence studies, and other su...